Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) Short Interest Update

Key Points

• Short interest fell 47% in August to 118,989 shares, representing 0.0% of outstanding shares and a days-to-cover ratio of 0.8.
• Coloplast shares rose 0.1% to $7.17, with a $16.16 billion market capitalization and a trading range of $5.64 to $10.03 over the past year.
• The company matched quarterly earnings expectations at $0.10 per share and exceeded revenue forecasts with $1.14 billion; analyst sentiment remains mixed, resulting in a consensus “Hold” rating.

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 118,989 shares, a decrease of 47.0% from the July 30th total of 224,453 shares. Based on an average daily trading volume, of 157,426 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.0% of the company's shares are short sold.

Coloplast A/S Trading Up 0.1%

Shares of Coloplast A/S stock traded up $0.01 during trading hours on Friday, reaching $7.17. The stock had a trading volume of 72,894 shares, compared to its average volume of 113,325. The firm has a market capitalization of $16.16 billion, a price-to-earnings ratio of 37.74, a P/E/G ratio of 2.70 and a beta of 0.13. Coloplast A/S has a 1 year low of $5.64 and a 1 year high of $10.03. The company has a current ratio of 1.75, a quick ratio of 1.09 and a debt-to-equity ratio of 1.66. The firm has a 50 day simple moving average of $6.44 and a two-hundred day simple moving average of $6.61.

Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) last released its quarterly earnings results on Tuesday, August 18th. The company reported $0.10 EPS for the quarter, hitting the consensus estimate of $0.10. Coloplast A/S had a return on equity of 38.81% and a net margin of 9.68%.The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.11 billion. As a group, equities research analysts anticipate that Coloplast A/S will post 0.4 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Kepler Capital Markets upgraded shares of Coloplast A/S to a "strong-buy" rating in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold".

About Coloplast A/S

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast's offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source